PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
-3.84%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$546M
AUM Growth
+$546M
(-5.4%)
Cap. Flow
+$43M
Cap. Flow
% of AUM
7.89%
Top 10 Holdings %
Top 10 Hldgs %
37.26%
Holding
117
New
22
Increased
53
Reduced
27
Closed
15
Top Buys
| 1 |
DexCom
DXCM
|
$16.8M |
| 2 |
HCA Healthcare
HCA
|
$13.8M |
| 3 |
Charles River Laboratories
CRL
|
$8.65M |
| 4 |
Cooper Companies
COO
|
$8.01M |
| 5 |
Zimmer Biomet
ZBH
|
$7.97M |
Top Sells
| 1 |
Danaher
DHR
|
$14.6M |
| 2 |
Lantheus
LNTH
|
$13.6M |
| 3 |
Waters Corp
WAT
|
$10.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.29M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.35M |
Sector Composition
| 1 | Healthcare | 99.65% |
| 2 | Industrials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Merus
MRUS
$5.04B
| $3.08M | 0.56% |
130,735
+62,854
| +93% | +$1.48M |
|
52
MoonLake Immunotherapeutics
MLTX
$3.78B
| $3.04M | 0.56% |
53,293
-26,707
| -33% | -$1.52M |
|
53
NeoGenomics
NEO
$1.06B
| $3.02M | 0.55% |
245,812
+9,965
| +4% | +$123K |
|
54
Crinetics Pharmaceuticals
CRNX
$3.26B
| $2.97M | 0.54% |
+100,000
| New | +$2.97M |
|
55
Establishment Labs
ESTA
$1.11B
| $2.97M | 0.54% |
60,530
+2,447
| +4% | +$120K |
|
56
Soleno Therapeutics
SLNO
$3.56B
| $2.95M | 0.54% |
+100,000
| New | +$2.95M |
|
|
PHLT
57
Performant Healthcare, Inc. Common Stock
PHLT
$602M
| $2.94M | 0.54% |
1,299,385
-147,030
| -10% | -$332K |
|
58
Evolent Health
EVH
$1.11B
| $2.81M | 0.52% |
103,320
-16,172
| -14% | -$440K |
|
59
Edwards Lifesciences
EW
$47.7B
| $2.77M | 0.51% |
+40,000
| New | +$2.77M |
|
60
Edgewise Therapeutics
EWTX
$1.54B
| $2.71M | 0.5% |
473,312
+19,065
| +4% | +$109K |
|
61
BridgeBio Pharma
BBIO
$9.91B
| $2.64M | 0.48% |
+100,000
| New | +$2.64M |
|
|
BCYC
62
Bicycle Therapeutics
BCYC
$492M
| $2.47M | 0.45% |
122,721
-49,564
| -29% | -$996K |
|
63
Disc Medicine
IRON
$2.14B
| $2.45M | 0.45% |
52,058
+2,058
| +4% | +$96.7K |
|
|
AKYA
64
DELISTED
Akoya BioSciences
AKYA
| $2.44M | 0.45% |
525,623
+54,623
| +12% | +$254K |
|
65
Lyra Therapeutics
LYRA
$11.8M
| $2.44M | 0.45% |
625,056
+25,056
| +4% | +$97.9K |
|
66
Acadia Pharmaceuticals
ACAD
$4.34B
| $2.41M | 0.44% |
115,777
+15,777
| +16% | +$329K |
|
67
NewAmsterdam Pharma
NAMS
$2.8B
| $2.3M | 0.42% |
249,024
+9,973
| +4% | +$92.3K |
|
68
Natera
NTRA
$23B
| $2.25M | 0.41% |
50,751
-24,288
| -32% | -$1.07M |
|
69
Quanterix
QTRX
$202M
| $2.09M | 0.38% |
77,087
+26,943
| +54% | +$731K |
|
70
Acumen Pharmaceuticals
ABOS
$84.2M
| $2.07M | 0.38% |
+499,814
| New | +$2.07M |
|
71
Mirum Pharmaceuticals
MIRM
$3.75B
| $2.06M | 0.38% |
65,050
+2,640
| +4% | +$83.4K |
|
72
Arvinas
ARVN
$580M
| $2.04M | 0.37% |
104,117
+4,117
| +4% | +$80.9K |
|
73
UroGen Pharma
URGN
$896M
| $2.04M | 0.37% |
+145,311
| New | +$2.04M |
|
|
LBPH
74
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.98M | 0.36% |
355,957
+14,370
| +4% | +$79.9K |
|
75
Esperion Therapeutics
ESPR
$490M
| $1.96M | 0.36% |
1,997,071
-135,238
| -6% | -$133K |
|